Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21FN2O2 |
Molecular Weight | 328.3806 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)C2=CC=CC=C2F
InChI
InChIKey=VAIOZOCLKVMIMN-PRJWTAEASA-N
InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-
Eplivanserin (SR 46349) is an antagonist of serotonin 2A receptor. Eplivanserin was previously in development by Sanofi-aventis in an effort to educate the public regarding this new mechanism of action for sleep aids. Eplivanserin was reviewed by the FDA as a potential treatment for patients with chronic insomnia, but the FDA requested additional information regarding benefit-risk and development of the drug has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00253968
Phase III study: 5 mg/day for 12 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135456190
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
130579-75-8
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL257704
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
7771
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
DTXSID601028413
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
EPLIVANSERIN
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
100000093074
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
SUB30142
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
WW-96
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
3CO94WO6DJ
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
C65517
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
DB12177
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)